PRAMEF2 (PRAME family member 2) is a BC-box containing substrate recognition subunit of the Cullin 2-based E3 ubiquitin ligase complex 1. Its primary function involves mediating polyubiquitylation and proteasomal degradation of LATS1, a key kinase in the Hippo/YAP signaling pathway 1. LATS1 degradation promotes nuclear accumulation of the transcriptional coactivator YAP, enhancing expression of proliferative and metastatic genes 1. PRAMEF2 expression is repressed under altered metabolic homeostasis in a FOXP3-dependent manner 1. In disease contexts, elevated PRAMEF2 levels correlate with increased nuclear YAP accumulation in advanced breast carcinoma grades, implicating PRAMEF2 in tumorigenesis 1. PRAMEF2 is a member of the PRAME cancer testis antigen family, serving as a prognostic marker for multiple cancers 1. Additionally, PRAMEF2 DNA methylation at specific CpG sites associates with cellular senescence, making it useful for quality control in therapeutic cell preparations 2. Recent evidence suggests PRAMEF2 upregulation in papillary thyroid cancer development 3. These findings establish PRAMEF2 as a pivotal regulator of YAP-dependent tumorigenesis with potential clinical applications in cancer prognosis and cellular therapy.